Synonyms: AL 6802 | AL6802 | SIM 6802 | SIM6802
simotinib is an approved drug (China only)
Compound class:
Synthetic organic
Comment: Simotinib is an oral, epidermal growth factor receptor tyrosine kinase inhibitor [1]. It was developed by Jiangsu Simcere Pharmaceutical Research Company in Nanjing, China. See also patent WO2010021918A1. Simotinib treatment is associated with serious adverse effects on gastrointestinal physiology [2].
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
Approved drug? | Yes. China (0) |
IUPAC Name ![]() |
N-(3-chloro-4-fluorophenyl)-6-[2-(5,8-dioxa-10-azadispiro[2.0.4^{4}.3^{3}]undecan-10-yl)ethoxy]-7-methoxyquinazolin-4-amine |
Synonyms ![]() |
AL 6802 | AL6802 | SIM 6802 | SIM6802 |
Database Links ![]() |
|
CAS Registry No. | 944258-89-3 (source: Scifinder) |
GtoPdb PubChem SID | 223365975 |
PubChem CID | 16735117 |
Search Google for chemical match using the InChIKey | OXWUWXCJDBRCCG-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | OXWUWXCJDBRCCG |
UniChem Compound Search for chemical match using the InChIKey | OXWUWXCJDBRCCG-UHFFFAOYSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | OXWUWXCJDBRCCG-UHFFFAOYSA-N |
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.
✖
Simotinib (links to external site)
Cat. No. HY-101820 |